To enhance prognostic accuracy, we took an innovative approach by combining preoperative PNI—identified as the most effective marker among nutritional and immune indices—with traditional tumor markers (CEA, CA19‐9, NSE, and CYFRA21‐1) in predicting postoperative recurrence for IB‐stage NSCLC. The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.